# A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

> **NCT06008288** · PHASE2 · RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 88 (estimated)

## Conditions studied

- KRAS P.G12C
- Pancreatic Cancer
- Solid Tumor

## Interventions

- **DRUG:** JAB-21822

## Key facts

- **NCT ID:** NCT06008288
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-27
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008288, "A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06008288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*